Showing 2391-2400 of 2705 results for "".
- 1 Million and Counting: Emsculpt Marks Treatment Milestonehttps://modernaesthetics.com/news/1-million-and-counting-emsculpt-marks-treatment-milestone/2473166/The Emsculpt family of products from BTL is the fastest aesthetic device brand to reach one million treatments, as indicated by Medical Insights. According to BTL, which reported the milestone, an average of 21 Emsculpt Classic treatments/unit a
- NeoGenesis Products Expand Beyond Oncology Skin Carehttps://modernaesthetics.com/news/neogenesis-products-expand-beyond-oncology-skin-care/2473164/NeoGenesis’ science-based skin and hair products have expanded from oncology aftercare to management of chronic skin conditions, aesthetic concerns, and wound support. The products were developed to provide a safe, natural approach to improving the quality of life of those undergoing oncolo
- Jeffrey Bettinger Joins Establishment Labs as Global Head of Peoplehttps://modernaesthetics.com/news/jeffrey-bettinger-joins-establishment-labs-as-global-head-of-people/2473162/Industry vet Jeffrey Bettinger is the new Global Head of People at Establishment Labs Holdings Inc. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants, and also
- RoC Skincare: Sunday is National Retinol Dayhttps://modernaesthetics.com/news/roc-skincare-sunday-is-national-retinol-day/2473161/Sunday marks the first-ever National Retinol Day. As people around the country turn their clocks back for daylight savings on November 7, RoC® is bringing attention to the use of retinol to help turn back the clock on fine lines and wrinkles. National Retinol Day has been registered
- Viewpoints: Recent CoolSculpting Media Coverage: Observations and Clarificationshttps://modernaesthetics.com/news/viewpoints-recent-coolsculpting-media-coverage-observations-and-clarifications/2473160/As an aesthetic key opinion leader, and longtime member of the Editorial Board of Modern Aesthetics® magazine, I would like to add observations and clarifications regarding some of the recent attention to CoolSculpting in the news. CoolSculpting is a technology that was d
- FDA Tightens Breast Implant Safety Requirements, Updates Study Resultshttps://modernaesthetics.com/news/fda-tightens-breast-implant-safety-requirements-updates-study-results/2473159/FDA is calling for stronger warnings on breast implants including a boxed warning, which lists such potential risks as infection, rupture, capsular contraction, breast implant illness, and breast implant-associated anaplastic large cell Lymphoma (BIA-ALCL).
- Meet the New Dermalogica Scholarship Winnershttps://modernaesthetics.com/news/meet-the-new-dermalogica-scholarship-winners/2473158/Dermalogica has awarded two New Beginnings scholarships to aesthetics students. Each scholarship recipient receives a $5,000 award and a professional development mentorship with a Dermalogica expert skin therapist. The New Beginnings scholarship is available to students enrolled i
- Galderma's Restylane Turns 25!https://modernaesthetics.com/news/galdermas-restylane-turns-25/2473147/Galderma’s Restylane is celebrating 25 years on the market. Since launching in Europe in 1996, Restylane has celebrated many milestones across the globe. This includes the first approval for use by the U.S. Food and Drug Administration (FDA) in 2003 and in China by the Nation
- Coming in November: The Science of Skincare Summithttps://modernaesthetics.com/news/coming-in-november-the-science-of-skincare-summit/2473146/A one-day event dedicted to education on skincare for medical and aesthetic professionals in all specialties, the Science of Skincare Summit November 6 at JW Marriott Essex House in New York City. Dermatologists Patti Farris, MD and Ted Lain, MD are co-founders of the program,
- ellacor Maker Cytrellis Closes Funding Roundhttps://modernaesthetics.com/news/ellacor-maker-cytrellis-closes-funding-round/2473145/Cytrellis has closed a $50 million Series C funding round. The financing was led by D1 Capital Partners and included participation from an additional new investor, Sands Capital, as well as existing institutional investors, ARCH Venture Partners and PFM Health Sciences. Proceeds will be